157 related articles for article (PubMed ID: 31309487)
1. Cysteinyl leukotriene receptor antagonism: a promising pharmacological strategy for lowering the severity of arthritis.
Venugopal N; Acharya P; Zarei M; Talahalli RR
Inflammopharmacology; 2019 Oct; 27(5):923-931. PubMed ID: 31309487
[TBL] [Abstract][Full Text] [Related]
2. Cysteinyl leukotriene receptor type 1 antagonist montelukast protects against injury of blood-brain barrier.
Zhou L; Sun X; Shi Y; Liu J; Luan G; Yang Y
Inflammopharmacology; 2019 Oct; 27(5):933-940. PubMed ID: 31313075
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms underlying the protective effect of leukotriene receptor antagonist montelukast against doxorubicin induced testicular injury in rats.
Mohamed MZ; Zenhom NM
Prostaglandins Other Lipid Mediat; 2020 Aug; 149():106447. PubMed ID: 32173485
[TBL] [Abstract][Full Text] [Related]
4. Montelukast Ameliorates 2K1C-Hypertension Induced Endothelial Dysfunction and Associated Vascular Dementia.
Gupta S; Singh P; Sharma B
Curr Hypertens Rev; 2024; 20(1):23-35. PubMed ID: 38192137
[TBL] [Abstract][Full Text] [Related]
5. The anti-inflammatory effect of montelukast, a cysteinyl leukotriene receptor-1 antagonist, against estradiol-induced nonbacterial inflammation in the rat prostate.
Said MM; Bosland MC
Naunyn Schmiedebergs Arch Pharmacol; 2017 Feb; 390(2):197-205. PubMed ID: 27909742
[TBL] [Abstract][Full Text] [Related]
6. Effects of montelukast, a cysteinyl-leukotriene type 1 receptor antagonist, on the pathogenesis of bleomycin-induced pulmonary fibrosis in mice.
Shimbori C; Shiota N; Okunishi H
Eur J Pharmacol; 2011 Jan; 650(1):424-30. PubMed ID: 21034736
[TBL] [Abstract][Full Text] [Related]
7. Leukotriene receptor antagonism with montelukast as a possible therapeutic for venous thromboembolism prophylaxis: An observational study.
Sutton SS; Magagnoli J; Cummings TH; Hardin JW
Prostaglandins Other Lipid Mediat; 2022 Aug; 161():106649. PubMed ID: 35595009
[TBL] [Abstract][Full Text] [Related]
8. Cysteinyl leukotriene receptor 1 antagonism prevents experimental abdominal aortic aneurysm.
Di Gennaro A; Araújo AC; Busch A; Jin H; Wågsäter D; Vorkapic E; Caidahl K; Eriksson P; Samuelsson B; Maegdefessel L; Haeggström JZ
Proc Natl Acad Sci U S A; 2018 Feb; 115(8):1907-1912. PubMed ID: 29432192
[TBL] [Abstract][Full Text] [Related]
9. Montelukast, a cysteinyl leukotriene receptor antagonist, exerts local antinociception in animal model of pain through the L-arginine/nitric oxide/cyclic GMP/K
Alizamani E; Ghorbanzadeh B; Naserzadeh R; Mansouri MT
Int J Neurosci; 2021 Oct; 131(10):1004-1011. PubMed ID: 32408781
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of sepsis-induced pancreatic injury by leukotriene receptor antagonism via modulation of oxidative injury, and downregulation of inflammatory markers in experimental rats.
Hagar HH; Alhazmi SM; Arafah M; Bayoumy NM
Naunyn Schmiedebergs Arch Pharmacol; 2024 May; 397(5):3425-3435. PubMed ID: 37962585
[TBL] [Abstract][Full Text] [Related]
11. Intercellular Ca2+ wave propagation involving positive feedback between CRAC channels and cysteinyl leukotrienes.
Di Capite J; Shirley A; Nelson C; Bates G; Parekh AB
FASEB J; 2009 Mar; 23(3):894-905. PubMed ID: 18978154
[TBL] [Abstract][Full Text] [Related]
12. Montelukast attenuates interleukin IL-1β-induced oxidative stress and apoptosis in chondrocytes by inhibiting CYSLTR1 (Cysteinyl Leukotriene Receptor 1) and activating KLF2 (Kruppel Like Factor 2).
Li Z; Wang J; Ma Y
Bioengineered; 2021 Dec; 12(1):8476-8484. PubMed ID: 34565285
[TBL] [Abstract][Full Text] [Related]
13. Oxidative renal damage in pyelonephritic rats is ameliorated by montelukast, a selective leukotriene CysLT1 receptor antagonist.
Tuğtepe H; Sener G; Cetinel S; Velioğlu-Oğünç A; Yeğen BC
Eur J Pharmacol; 2007 Feb; 557(1):69-75. PubMed ID: 17173892
[TBL] [Abstract][Full Text] [Related]
14. Acute effects of the cys-leukotriene-1 receptor antagonist, montelukast, on experimental colitis in rats.
Holma R; Salmenperä P; Riutta A; Virtanen I; Korpela R; Vapaatalo H
Eur J Pharmacol; 2001 Oct; 429(1-3):309-18. PubMed ID: 11698051
[TBL] [Abstract][Full Text] [Related]
15. Ameliorating effect of leukotriene receptor antagonist in multi-organ toxicity induced in rat offspring, a possible role for epidermal growth factor.
Abdelzaher WY; Rofaeil RR; Abdel-Hafez SMN; Atta M; Bahaa El-Deen MA; Ali DM
Immunopharmacol Immunotoxicol; 2021 Apr; 43(2):183-191. PubMed ID: 33504223
[No Abstract] [Full Text] [Related]
16. Cysteinyl leukotriene receptor antagonist montelukast ameliorates acute lung injury following haemorrhagic shock in rats.
Al-Amran FG; Hadi NR; Hashim AM
Eur J Cardiothorac Surg; 2013 Feb; 43(2):421-7. PubMed ID: 22851661
[TBL] [Abstract][Full Text] [Related]
17. Possible Therapeutic Potential of Cysteinyl Leukotriene Receptor Antagonist Montelukast in Treatment of SARS-CoV-2-Induced COVID-19.
Dey M; Singh RK
Pharmacology; 2021; 106(9-10):469-476. PubMed ID: 34350893
[TBL] [Abstract][Full Text] [Related]
18. Montelukast, a cysteinyl leukotriene receptor-1 antagonist protects against hippocampal injury induced by transient global cerebral ischemia and reperfusion in rats.
Saad MA; Abdelsalam RM; Kenawy SA; Attia AS
Neurochem Res; 2015 Jan; 40(1):139-50. PubMed ID: 25403620
[TBL] [Abstract][Full Text] [Related]
19. Effect of a cysteinyl leukotriene receptor antagonist on experimental emphysema and asthma combined with emphysema.
Ikeda G; Miyahara N; Koga H; Fuchimoto Y; Waseda K; Kurimoto E; Taniguchi A; Tanimoto Y; Kataoka M; Tanimoto M; Kanehiro A
Am J Respir Cell Mol Biol; 2014 Jan; 50(1):18-29. PubMed ID: 23937413
[TBL] [Abstract][Full Text] [Related]
20. [Effects of agonist and antagonist of cysteinyl leukotriene receptors on differentiation of rat glioma C6 cells].
Cai BL; Wang XX; Yu SY; Huang XQ; Zhang XY; Fang SH; Lu YB; Zhang WP; Wei EQ
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2011 Mar; 40(2):139-44. PubMed ID: 21488208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
